Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade
Abdul Shahid Poovathum Parambil, Abul Hussain Mirsa, Azgar Abdul Rasheed, Arun Vasudevan · 2026
Read Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade by Abdul Shahid Poovathum Parambil, Abul Hussain Mirsa, Azgar Abdul Rasheed, Arun Vasudevan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13597254.txt.
Description
Abdul Shahid Poovathum Parambil and co-workers report real-world results of dual HER2 blockade before breast cancer surgery in India, in a 2026 paper. This aggressive cancer subtype responds well to paired targeted drugs plus chemotherapy in trials. Evidence from routine Indian practice was missing.
Seventy-four patients at a Kerala hospital received the two drugs by vein or under the skin. Just over half achieved complete disappearance of invasive cancer in the surgical specimen. The under-skin group scored lower than the vein group, though the gap was not quite significant. Disease stage predicted response in adjusted analysis. The authors present the results as a benchmark for local practice.
Catalog record
| CREATOR | Abdul Shahid Poovathum Parambil, Abul Hussain Mirsa, Azgar Abdul Rasheed, Arun Vasudevan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |